Related Experiment Videos
Pediatric liver transplantation with daclizumab induction
Thomas G Heffron1, Todd Pillen, Gregory A Smallwood
1Emory University School of Medicine, Department of Surgery, Atlanta, Georgia, USA.
Transplantation
|June 28, 2003
Summary
Single-dose daclizumab induction therapy after pediatric liver transplantation significantly reduced early rejection episodes. This approach is safe and effective, allowing delayed tacrolimus use while maintaining patient and graft survival.
Area of Science:
- Immunology
- Transplantation Medicine
- Pediatric Hepatology
Background:
- Non-T-cell depleting monoclonal antibodies are increasingly used for induction therapy post-transplantation.
- Daclizumab, an antibody targeting the CD25 cell, was evaluated as a single-dose induction agent.
Purpose of the Study:
- To assess the efficacy and renal function of daclizumab as a single-dose induction agent in pediatric liver transplantation.
- To evaluate the potential to spare calcineurin inhibitor (tacrolimus) use for the initial 7 days post-transplant.
Main Methods:
- 81 pediatric liver transplant recipients (89 grafts) were analyzed.
- Treatment group (n=61) received immediate post-transplant daclizumab (1 mg/kg) plus mycophenolate and steroids, with tacrolimus initiated on postoperative day 7.
- Control group received immediate tacrolimus, mycophenolate, and steroids without induction therapy.
Main Results:
- The induction group showed significantly fewer rejections within 30 days (14.8% vs. 50%; P=0.003).
- Patients not receiving induction had a 3.39-fold increased risk of early rejection.
- Two-year patient survival was 93.2% (induction) vs. 85% (control); graft survival was 87.8% vs. 72.7% respectively.
Conclusions:
- Single-dose daclizumab (1 mg/kg) post-pediatric liver transplant is safe and effective.
- This induction strategy reduces early rejections within 30 days.
- Delayed tacrolimus initiation is feasible with daclizumab induction.